Latest Science
Osimertinib-Resistant Cell Lines and Models
Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug. Resistance to osimertinib includes both on-target and off-target mechanisms. With the use of osimertinib for advanced EGFR-mutant NSCLC increasing, the development of targeted therapies toward osimertinib resistance represents an unmet medical need. To support research …Read More >
Control of the Antitumor Activity and Specificity of CAR T Cells via Organic Adapters Covalently Tethering the CAR to Tumor Cells
On-target, off-tumor toxicity is a specific type of toxic side effect that limits the anticancer applicability of chimeric antigen receptor (CAR) T cells. In our latest publication, WuXi AppTec scientists contributed to a study describing how the tumor-targeting specificity and activity of T cells with a CAR (consisting of an antibody that catalytically forms a …Read More >
Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors
The KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinomas (PDAC), making this an important drug target. WuXi AppTec scientists recently contributed to a research article in ACS Med. Chem. Letters describing the optimization of a series of potent and selective KRAS G12D inhibitors through a structure-based drug design approach. The …Read More >
Anti-Tumor Nucleic Acid Drug Discovery Platform
Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects. To address these challenges, WuXi AppTec offers a full suite of nucleic acid-related services, including target validation, in vitro screening and cell-based functional assays, drug exposure analysis, biodistribution evaluation, PK/PD/efficacy testing, and safety assessment. Leverage our comprehensive platform to accelerate …Read More >
Enhertu-Induced Resistant Tumor Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies. However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models. WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused …Read More >
